Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).
Abad
S
S
Service de Médecine Interne 2, Hôpital Cochin-Saint Vincent de Paul, Université René Descartes, Paris, France. abadsp40@aol.com
Gyan
E
E
Moachon
L
L
Bouscary
D
D
Sicard
D
D
Dreyfus
F
F
Blanche
P
P
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008297:Male; D009163:Mycobacterium bovis; D014376:Tuberculosis / Q000209:etiology* / Q000382:microbiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab